Live Breaking News & Updates on பால் சோய்

Stay updated with breaking news from பால் சோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Esperion Therapeutics, inc (ESPR) Q2 2021 Earnings Call Transcript


Operator
Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir.
Benjamin Church
Head, Corporate Communications & Investor Relations
Thank you, operator. Good morning and welcome to Esperion s Second Quarter 2021 Financial Results and Company Update Conference Call. I m Ben Church and I m responsible for Investor Relations and Corporate Communications here at Esperion.
I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. ....

United States , United Kingdom , Morgan Stanley , Rick Bartram , Sheldon Koenig , Jessica Fye , Zetia Vytorin , Joseph Thome Cowen , Joseph Thome , Eric Warren , Thomas Shrader , Michael Yee , Steven Nissen , Geoff Meacham , Olivia Brayer , Jason Butler , Daiichi Sankyo , Joanne Foody , Charlie Goldman Sachs , Joanne Micale Foody , Tom Shrader , Michael Yee Jefferies , Paul Choi , Company Update Conference Call , Goldman Sachs , Ben Church ,

Global Blood Therapeutics (GBT) Q2 2021 Earnings Call Transcript


Operator
Greetings, and welcome to Global Blood Therapeutics conference call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Steven Immergut. Please go ahead, sir.
Steven Immergut
Investor Relations
Thank you, and welcome to GBT s conference call to discuss the company s financial results for the second-quarter 2021 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, will provide an update on our progress in the second quarter; Jeff Farrow, our chief financial officer, will review our financial results; David Johnson, or DJ, our chief commercial officer, will give an update on the Oxbryta launch; Dr. ....

United States , United Kingdom , City Of , David Johnson , Jason Gerberry , Kim Smith Whitley , Steven Immergut , Alethia Young , Courtney Roberts , Alethia Young Cantor Fitzgerald , Andrew Berens , Yanan Zhu , Elemer Piros , Paul Choi Goldman Sachs , Mark Breidenbach , Alan Anderson , Baral Cowen , Paul Choi , Jeff Farrow , Goldman Sachs , Kaiser Family Foundation , National Strategic Plan On Sickle Cell Disease , Sickle Cell Disease Association Of America , Mark Breidenbach Oppenheimer Co , National Academies Of Sciences , Company Analyst ,

Myovant Sciences Ltd. (MYOV) Q1 2021 Earnings Call Transcript


Operator
Good day, everyone, and welcome to Myovant Sciences first-quarter of fiscal year 2021 earnings conference call. Today s call is being recorded. At this time, I would like to turn the call over to Ryan Crowe, vice president of investor relations at Myovant. Please go ahead.
Ryan Crowe
Vice President of Investor Relations
Thank you, operator. Good morning and thanks for joining us today to review the financial results of Myovant s first quarter of fiscal year 2021 and to discuss other corporate and business updates. Joining me for today s call are Dave Marek, Myovant s chief executive officer; Frank Karbe, president and chief financial officer; Lauren Merendino, chief commercial officer; and Dr. Juan Camilo Arjona, chief medical officer. ....

Sumitomo Dainippon Pharma , Lauren Merendino , Phil Nadeau Cowen , Josh Schimmer , Jason Butler , Bryan Crowe , Frank Karbe , Juan Camilo , Paul Choi Goldman Sachs , Juan Camilo Arjona , Brian Skorney , Paul Choi , Dave Marek , Phil Nadeau , Deric Joseph , Brian Skorney Baird , Myovant Sciences Ltd , Myovant Sciences , European Commission , Goldman Sachs , Company Analyst , Gedeon Richter , Investor Relations , Withdrawal Study , Liberty Clinical Trial , Liberty Clinical ,